Stratos Wealth Advisors LLC Raises Stock Holdings in Stryker Co. (NYSE:SYK)

Stratos Wealth Advisors LLC increased its stake in shares of Stryker Co. (NYSE:SYK) by 5.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,409 shares of the medical technology company’s stock after purchasing an additional 232 shares during the quarter. Stratos Wealth Advisors LLC’s holdings in Stryker were worth $1,588,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in SYK. Czech National Bank boosted its position in Stryker by 8.1% during the third quarter. Czech National Bank now owns 69,843 shares of the medical technology company’s stock worth $25,231,000 after acquiring an additional 5,235 shares during the last quarter. Dynamic Advisor Solutions LLC boosted its holdings in shares of Stryker by 2.3% during the third quarter. Dynamic Advisor Solutions LLC now owns 2,990 shares of the medical technology company’s stock worth $1,080,000 after purchasing an additional 67 shares during the last quarter. Atomi Financial Group Inc. boosted its holdings in shares of Stryker by 2.3% during the third quarter. Atomi Financial Group Inc. now owns 2,091 shares of the medical technology company’s stock worth $755,000 after purchasing an additional 47 shares during the last quarter. Sugarloaf Wealth Management LLC increased its stake in Stryker by 32.7% in the third quarter. Sugarloaf Wealth Management LLC now owns 446 shares of the medical technology company’s stock valued at $161,000 after purchasing an additional 110 shares during the last quarter. Finally, Reliant Investment Management LLC lifted its position in Stryker by 0.9% during the third quarter. Reliant Investment Management LLC now owns 15,200 shares of the medical technology company’s stock worth $5,491,000 after buying an additional 138 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on SYK. Needham & Company LLC restated a “buy” rating and issued a $442.00 price target on shares of Stryker in a report on Wednesday, January 29th. Robert W. Baird boosted their target price on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. increased their price target on shares of Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Canaccord Genuity Group boosted their price objective on shares of Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Finally, BTIG Research increased their target price on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $419.37.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 5.50% of the stock is currently owned by corporate insiders.

Stryker Price Performance

Shares of SYK stock opened at $399.01 on Thursday. The firm has a fifty day simple moving average of $376.87 and a 200-day simple moving average of $364.00. The company has a market capitalization of $152.11 billion, a PE ratio of 51.42, a price-to-earnings-growth ratio of 2.78 and a beta of 0.96. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the previous year, the company posted $3.46 earnings per share. Equities research analysts anticipate that Stryker Co. will post 13.5 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.84%. Stryker’s dividend payout ratio is presently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.